graft rejection
6.IL-lra blocks cellular responses to IL-1 by binding almost irreversibly to the BL-1 receptor without triggering signal transduction. Animal experiments indicated that IL-lra can markly prolong the survival time of corneal allografts by inhibiting graft rejection, and prevent vascular growth of corneal allografts, although the mechanism is still unclear.
7.Six of the 22 patients who did not receive donor lymphocyte infusion (DLI) all died of relapse. Adoptive immunotherapy was used to treat the remaining 16 patients. Before the time of relapse or graft rejection, STR-PCR indicated decrease of DC in 12 of the 16 patients, with levels ranging from 24.8%-86.2%.

